@article{ATM13246,
author = {Giuseppe Lippi and Emmanuel J. Favaloro},
title = {Laboratory monitoring of direct oral anticoagulants (DOACs)—The perfect storm?},
journal = {Annals of Translational Medicine},
volume = {5},
number = {1},
year = {2017},
keywords = {},
abstract = {The current armamentarium of anticoagulant drugs is broad and multifaceted (1) (Figure 1). Historically, anticoagulant treatment has been based on administration of vitamin K antagonists (VKAs; especially warfarin and syntrom), which mainly act by reducing the synthesis of active vitamin K-dependent factors (factors II, VII, IX and X). Due to a long lag phase of anticoagulation induction, the additional inhibitory effect on two physiological inhibitors of blood coagulation (i.e., protein C and protein S) and the narrow therapeutic range, VKAs have been supported for decades with initial and/or additional use of heparins/derivatives (1).},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/13246}
}